Back
54
Day Range
$58.43
$59.99
52-Week Range
$47.32
$87.32
Volume
307,419
50D / 200D Avg
$65.06
/
$65.66
Prev Close
$58.58
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 16.3 | 0.4 |
| P/B | 3.3 | 2.9 |
| ROE % | 18.8 | 3.7 |
| Net Margin % | 12.3 | 3.8 |
| Rev Growth 5Y % | 11.8 | 10.0 |
| D/E | 1.5 | 0.2 |
Key Takeaways
Revenue grew 11.82% annually over 5 years — strong growth
Earnings grew 42.64% over the past year
ROE of 18.83% — decent returns on equity
Generating 142.45M in free cash flow
PEG of 0.44 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.87%
Growth
Revenue Growth (5Y)
11.82%
Revenue (1Y)3.95%
Earnings (1Y)42.64%
FCF Growth (3Y)-6.48%
Quality
Return on Equity
18.83%
ROIC8.13%
Net Margin12.32%
Op. Margin16.30%
Safety
Debt / Equity
1.49
Current Ratio1.62
Interest Coverage22.76
Valuation
P/E Ratio
16.32
P/B Ratio3.33
EV/EBITDA16.48
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 3.95% | Revenue Growth (3Y) | 7.91% |
| Earnings Growth (1Y) | 42.64% | Earnings Growth (3Y) | 20.54% |
| Revenue Growth (5Y) | 11.82% | Earnings Growth (5Y) | 20.52% |
| Profitability | |||
| Revenue (TTM) | 1.36B | Net Income (TTM) | 167.68M |
| ROE | 18.83% | ROA | 6.84% |
| Gross Margin | 57.21% | Operating Margin | 16.30% |
| Net Margin | 12.32% | Free Cash Flow (TTM) | 142.45M |
| ROIC | 8.13% | FCF Growth (3Y) | -6.48% |
| Safety | |||
| Debt / Equity | 1.49 | Current Ratio | 1.62 |
| Interest Coverage | 22.76 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 16.32 | P/B Ratio | 3.33 |
| P/S Ratio | 2.01 | PEG Ratio | 0.44 |
| EV/EBITDA | 16.48 | Dividend Yield | 0.00% |
| Market Cap | 2.74B | Enterprise Value | 3.65B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.36B | 1.31B | 1.17B | 993.20M | 870.46M |
| Net Income | 167.68M | 117.56M | 115.40M | 43.38M | 79.47M |
| EPS (Diluted) | 3.31 | 2.29 | 2.24 | 0.84 | 1.55 |
| Gross Profit | 778.55M | 711.92M | 622.87M | 530.77M | 428.45M |
| Operating Income | 221.82M | 164.88M | 156.03M | 80.75M | 89.75M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.45B | 2.20B | 1.93B | 1.86B | 1.82B |
| Total Liabilities | 1.63B | 1.24B | 1.12B | 1.11B | 1.09B |
| Shareholders' Equity | 820.84M | 959.96M | 818.00M | 749.42M | 731.67M |
| Total Debt | 1.22B | 807.79M | 765.89M | 780.79M | 778.28M |
| Cash & Equivalents | 306.76M | 178.80M | 284.47M | 259.50M | 192.31M |
| Current Assets | 934.98M | 768.90M | 769.72M | 756.03M | 693.55M |
| Current Liabilities | 578.11M | 300.38M | 251.82M | 442.27M | 253.50M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#145 of 326
Recent Activity
Entered
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026